XML 126 R114.htm IDEA: XBRL DOCUMENT v3.22.2
Supplemental Financial Information - Cash Flows (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Cash flows from operating activities          
Net income $ 248.9 $ 946.5 $ 843.7 $ 1,837.4  
Adjustments to reconcile net income to net cash flows from operating activities:          
Depreciation and amortization     59.9 26.8  
Right-of-use asset impairment, net of broker fees     0.0 24.8  
Equity-based compensation 45.4 47.2 85.1 79.6  
Non-cash performance allocations and incentive fees     (89.8) (1,703.9)  
Non-cash principal investment income     (365.1) (303.8)  
Other non-cash amounts     (11.9) 5.5  
Purchases of investments     (456.8) (103.4)  
Proceeds from the sale of investments     287.1 398.2  
Payments of contingent consideration     (5.7) (49.9)  
Changes in deferred taxes, net     55.9 481.9  
Change in due from affiliates and other receivables     (65.3) (14.9)  
Change in deposits and other     (7.1) (26.6)  
Change in accounts payable, accrued expenses and other liabilities     (67.2) 25.4  
Change in accrued compensation and benefits     (372.1) (113.9)  
Change in due to affiliates     2.8 24.5  
Change in lease right-of-use assets and lease liabilities     (4.6) 4.6  
Change in deferred revenue     (12.9) 35.6  
Net cash provided by (used in) operating activities     (558.5) 595.3  
Cash flows from investing activities          
Purchases of fixed assets, net     (17.4) (17.6)  
Purchase of CBAM intangibles and investments, net     (618.4) 0.0  
Proceeds from sale of MRE, net of cash sold     0.0 5.9  
Net cash used in investing activities     (635.8) (11.7)  
Cash flows from financing activities          
Issuance of 4.625% subordinated notes due 2061, net of financing costs     0.0 484.2  
Payments on CLO borrowings     (9.0) (229.4)  
Proceeds from CLO borrowings, net of financing costs     41.1 87.7  
Dividends to common stockholders     (207.1) (177.4)  
Payment of deferred consideration for Carlyle Holdings units     (68.8) (68.8)  
Contributions from non-controlling interest holders     166.9 44.4  
Distributions to non-controlling interest holders     (156.6) (42.9)  
Common shares issued for performance allocations     36.5 0.0  
Common shares repurchased     (105.3) (25.0)  
Change in due to/from affiliates financing activities     (27.7) 12.8  
Net cash provided by financing activities     75.9 69.7  
Effect of foreign exchange rate changes     (46.9) (25.7)  
Increase (decrease) in cash, cash equivalents and restricted cash     (1,165.3) 627.6  
Cash, cash equivalents and restricted cash, beginning of period     2,475.1 989.6  
Cash, cash equivalents and restricted cash, end of period 1,309.8 1,617.2 1,309.8 1,617.2  
Reconciliation of cash, cash equivalents and restricted cash, end of period:          
Cash and cash equivalents 1,308.9 1,586.2 1,308.9 1,586.2 $ 2,469.5
Restricted cash 0.9 31.0 0.9 31.0 5.6
Total cash, cash equivalents and restricted cash, end of period 1,309.8 1,617.2 1,309.8 1,617.2 2,475.1
Cash and cash equivalents held at Consolidated Funds 230.7 187.5 230.7 187.5 147.8
Consolidated Operating Entities          
Cash flows from operating activities          
Net income     814.0 1,837.2  
Adjustments to reconcile net income to net cash flows from operating activities:          
Depreciation and amortization     59.9 26.8  
Right-of-use asset impairment, net of broker fees     0.0 24.8  
Equity-based compensation     85.1 79.6  
Non-cash performance allocations and incentive fees     (94.6) (1,703.9)  
Non-cash principal investment income     (318.4) (313.3)  
Other non-cash amounts     (11.9) 5.5  
Purchases of investments     (470.3) (161.3)  
Proceeds from the sale of investments     298.2 418.5  
Payments of contingent consideration     (5.7) (49.9)  
Changes in deferred taxes, net     55.9 481.9  
Change in due from affiliates and other receivables     (64.8) (14.8)  
Change in deposits and other     (7.1) (26.6)  
Change in accounts payable, accrued expenses and other liabilities     (67.2) 25.4  
Change in accrued compensation and benefits     (372.1) (113.9)  
Change in due to affiliates     2.8 24.5  
Change in lease right-of-use assets and lease liabilities     (4.6) 4.6  
Change in deferred revenue     (12.9) 35.6  
Net cash provided by (used in) operating activities     (113.7) 580.7  
Cash flows from investing activities          
Purchases of fixed assets, net     (17.4) (17.6)  
Purchase of CBAM intangibles and investments, net     (618.4) 0.0  
Net cash used in investing activities     (635.8) (11.7)  
Cash flows from financing activities          
Issuance of 4.625% subordinated notes due 2061, net of financing costs     0.0 484.2  
Payments on CLO borrowings     (9.0) (229.4)  
Proceeds from CLO borrowings, net of financing costs     41.1 87.6  
Dividends to common stockholders     (207.1) (177.4)  
Payment of deferred consideration for Carlyle Holdings units     (68.8) (68.8)  
Contributions from non-controlling interest holders     4.4 7.4  
Distributions to non-controlling interest holders     (36.6) (22.9)  
Common shares issued for performance allocations     36.5 0.0  
Common shares repurchased     (105.3) (25.0)  
Change in due to/from affiliates financing activities     (27.8) 12.8  
Net cash provided by financing activities     (372.6) 68.5  
Effect of foreign exchange rate changes     (43.2) (9.9)  
Increase (decrease) in cash, cash equivalents and restricted cash     (1,165.3) 627.6  
Cash, cash equivalents and restricted cash, beginning of period     2,475.1 989.6  
Cash, cash equivalents and restricted cash, end of period 1,309.8 1,617.2 1,309.8 1,617.2  
Supplemental non-cash disclosures          
Issuance of common shares related to the acquisition of CBAM intangibles and investments     194.5 0.0  
Reconciliation of cash, cash equivalents and restricted cash, end of period:          
Cash and cash equivalents 1,308.9 1,586.2 1,308.9 1,586.2  
Restricted cash 0.9 31.0 0.9 31.0  
Total cash, cash equivalents and restricted cash, end of period 1,309.8 1,617.2 1,309.8 1,617.2 $ 2,475.1
Cash and cash equivalents held at Consolidated Funds $ 230.7 $ 187.5 230.7 $ 187.5  
Consolidated Operating Entities | Subordinated Notes Due 2061          
Reconciliation of cash, cash equivalents and restricted cash, end of period:          
Interest rate (percent)   4.625%   4.625%  
Consolidated Operating Entities | MRE          
Cash flows from investing activities          
Proceeds from sale of MRE, net of cash sold     $ 0.0 $ 5.9